When a member is referred for complex, high-cost care, we can help you evaluate and guide the terms and process.
We provide options and knowledge about where to receive care, and can compare available metrics to assist you in the decision-making process. To do this, we monitor and analyze comprehensive data, the clinical pipeline, existing reimbursement policies, compliance regulations and industry trends to fully understand the market.
Turn to us for:
We monitor the cell and gene preclinical and clinical trial landscape to identify conditions being targeted for genetic and cellular therapy. Our pipeline curation process spans from identification of conditions targeted by emerging cellular and gene therapies through pre-clinical, monitoring of the clinical trials, post-market approvals, the manufacturing market, and supply chain development. Our ETS medical services team of registered nurse clinical consultants offer content, consultation and a condition-specific knowledge base for these conditions and therapies in the pipeline.
We regularly convene expert clinical panels based on the emerging gene and cellular therapy pipeline that include leading medical researchers, clinical teams and facilities with experience and knowledge in each chosen therapeutic area.
We offer a full complement of materials and documents to help your team navigate this changing environment, with content available through subscription to our online ETS Knowledge Center Portal.
Let ETS consulting services help you with plan design, analytics, clinical data modeling, policy design, and more related to high-cost and complex conditions. We specialize in these rare and high-cost conditions that many organizations do not have the scale to tackle. We offer a wealth of information, experience and content to design a solution specific to your needs.